Novavax’s adjuvant, Matrix-M, has taken center stage as it is now the key ingredient in the second-ever malaria vaccine recommended by the World Health Organization (WHO). This groundbreaking development is set to make a significant impact on malaria prevention in Africa.
The Serum Institute of India (SII) has been granted a license by Novavax to use the Matrix-M adjuvant for production, specifically targeting endemic countries. Notably, Matrix-M had previously been tested in a vaccine candidate from the prestigious University of Oxford, showcasing its potential efficacy.
The introduction of this new malaria vaccine is expected to help alleviate the overwhelming demand for preventive measures in Africa. The SII has already swung into action, commencing production of the R21/Matrix-M vaccine. Over the next two years, they aim to scale up production to a staggering 200 million doses. Furthermore, the affordability of this vaccine is a game-changer, with each dose being priced at less than $5.
It is worth mentioning that the Serum Institute faced setbacks in the past due to the Indian government’s request to restrict COVID-19 vaccine exports to Africa. This strained the relationship between the institute and sub-Saharan countries. However, the collaboration between SII and Novavax for the malaria vaccine signifies a positive shift in their partnership.
The limited vaccine manufacturing options within Africa have led to widespread calls for equity in the Global South. As a result, major pharmaceutical companies like Pfizer, Moderna, and BioNTech have pledged commitments to increase manufacturing capabilities in Africa. Though some efforts seem to have waned, partnerships and investments are being made to fulfill the African Union’s goal of producing 60% of the continent’s vaccine requirements by 2040.
In order to meet the growing demand for vaccines, the Serum Institute has established a partnership with Aspen Pharmacare to produce multiple vaccines. However, the production of the malaria vaccine is primarily taking place in India, emphasizing the significance of this breakthrough for African countries.
In conclusion, Novavax’s Matrix-M adjuvant’s role in the second-ever malaria vaccine recommended by the WHO is a significant milestone. With the Serum Institute of India leading the charge in production, Africa’s battle against malaria is set to receive a major boost. Efforts to increase vaccine manufacturing in Africa are ongoing, and partnerships like those between the Serum Institute and Aspen Pharmacare are vital in meeting the continent’s vaccine requirements.
“Social media scholar. Reader. Zombieaholic. Hardcore music maven. Web fanatic. Coffee practitioner. Explorer.”